NASDAQ: KLRA
Kailera Therapeutics, Inc.CIK 0002096997 · Pharmaceutical Preparations
10-Q
Filed May 26, 2026
· Period ending Mar 31, 2026
Kailera debuts Q1 2026: $79M loss, $582M cash, IPO adds $719M runway into mid-2028
5 material changes detected. Sign up free to read the summary.
8-K
Filed May 26, 2026
· Period ending May 26, 2026
Kailera Therapeutics reports Q1 2026 financial results
1 material change detected. Sign up free to read the summary.
Partner
Trade KLRA commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
8-K
Filed Apr 20, 2026
· Period ending Apr 20, 2026
Summary not yet generated.